Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation전임상 평가를 통해 SARS-CoV-2 및 이의 변이체에 대한 범-CoV 융합 억제제에 대한 구조 및 기능 기반Article Published on 2021-07-292022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 변종, 신약개발, 치료제, [키워드] (alpha administration African Alpha animal models antiviral activity antiviral agent Antiviral agents B.1.1.7 Caco2 Calu Calu-3 Cell fusion cell line cell lines cholesterol clinical development COVID-19 pandemic crystal structure D614G E484K Economy effective functional Gamma hACE2 HR1 domain Infection Infectious diseases inhibitor inhibitors intestinal tissues lung Mutation N501Y peptide peptides pseudotyped SARS-CoV-2 public health reduced S protein safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 S protein SARS-CoV-2 variant significantly South structural biology target the SARS-CoV-2 transgenic mice Vaccines variant variants Viral viral titer viral titers [DOI] 10.1038/s41392-021-00712-2 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine DevelopmentMolecular Biosciences Published on 2021-07-282022-10-31 Journal: Frontiers in Molecular Biosciences [Category] COVID-19, [키워드] acute respiratory syndrome affecting alleviate antibody antigenic target antiviral therapeutics approach can be used cell lines clinical development conserved Coronaviral coronavirus coronavirus disease Coronavirus pandemic Coronavirus-2 COVID COVID-19 COVID-19 pandemic cross-react demonstrated detect development Diagnosis diagnosis of COVID-19 diagnostic diagnostics domain effective ELISA extrapolation facilitate host cell receptor Human IgM and IgG in vitro study Infection inhibiting interact Lateral flow immunoassays mAb mAbs molecular monoclonal antibody Mortality N-terminal domain neutralize Neutralizing neutralizing antibody pandemic platform polyclonal antibody Prevent Prophylaxis RBD Receptor binding domain Region researcher S-protein S1 and S2 S1 domain S2 domain SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection selection pressure sequence similarity Serological assay spike spike gene spike glycoprotein the RBD Treatment trimer Vaccine Vaccines Viral protein virus virus-cell membrane fusion [DOI] 10.3389/fmolb.2021.607886 PMC 바로가기 [Article Type] Molecular Biosciences
Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatmentsResearch article Published on 2021-07-282022-10-05 Journal: Heliyon [Category] 신약개발, 치료법, 치료제, [키워드] Abbreviated Profile of Drugs (APOD) ADMET administer Analysis APOD approved approved drug Cancer category clinical development clinical trial coronavirus disease COVID-19 COVID-19 treatment criteria database dataset demonstrated Dexamethasone drug Drug discovery Drug safety profile effective EIDD-2801 examined facilitated FDA food GDC-0941 imperative inhibitors methodology moderate molnupiravir organ-specific P450 Pharmacokinetic prediction profile progression recalled resources safety profile tested toxicities transmitted Transport withdrawn [DOI] 10.1016/j.heliyon.2021.e07666 [Article Type] Research article
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice마우스에서 SARS-CoV-2 및 B.1.351 변이체의 예방 및 치료Article Published on 2021-07-272022-09-11 Journal: Cell Reports [Category] SARS, 변종, 진단, 치료제, [키워드] antibody antibody combination Antiviral Antiviral effect B.1.351 B.1.351 variant causative agent clinical care clinical development clinical trials Combination coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated Health human monoclonal antibodies Human monoclonal antibody IMPROVE Improving in vivo individual infected with SARS-CoV-2 Infection initiated mAb mAbs mice monoclonal monoclonal antibodies outcome Patient prevention provided RDV Remdesivir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 variants Support therapeutic efficacy therapy These data treat variant variants VoC [DOI] 10.1016/j.celrep.2021.109450 PMC 바로가기 [Article Type] Article
Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy확장 가능한 약독화 생 SARS-CoV-2 백신 후보, 전임상 안전성 및 효능 입증423 Published on 2021-07-202022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] Coronavirus, SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus added addition administration Amino acid amino acid sequence antibody antigenic antigenic drift approach Brain clinical development clinical testing codon deoptimization combating component condition conditions coronavirus COVID-19 COVID-19 pandemic deleted dose Effect Efficacy emerging disease engage feasibility furin furin cleavage site furin cleavage site deletion hamster hamsters herd immunity host immune system IgG antibody Immunity immunization in vitro in vivo model inoculated intranasal intranasally live attenuated Live virus lung Lung pathology mass immunization mass vaccination Mesocricetus mutations parental plaque reduction neutralization potency Protective recipients reduced reversion SARS-CoV-2 SARS-CoV-2 vaccine segment sequence Significance silent spike IgG Spike protein Support synonymous Syrian golden hamster Syrian Golden hamsters temperature temperature sensitive the spike protein the vaccine undetectable vaccination Vaccine vaccine candidate vaccine candidates vaccine strain viral genome Viral load Viral protein Viral proteins viral spike protein viral titers virus virus growth weight loss wild-type WT virus [DOI] 10.1073/pnas.2102775118 PMC 바로가기 [Article Type] 423
Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19사설: Tocilizumab, 인간화 치료 IL-6 수용체(IL-6R) 단클론항체 및 중증 COVID-19에 대한 미래 조합 요법Editorial Published on 2021-07-192022-09-12 Journal: Medical science monitor : international medical jo [Category] 진단, [키워드] antibody approved authorization CAR chimeric antigen receptor clinical development clinical trial combination therapies combination treatment COVID-19 COVID-19 therapy CRS Cytokine release syndrome develop disease drug editorial Efficacy Emergency EUA FDA food Future giant cell arteritis Hospital admission hospitalized patient humanized humanized monoclonal antibody IL-6 IL-6 receptor IL-6R Immunosuppressed individual infected with SARS-CoV-2 juvenile idiopathic arthritis moderate monoclonal antibody Patient Proinflammatory cytokine recovery reduce REMAP-CAP rheumatoid arthritis SARS-COV-2 infection severe COVID-19 severity of COVID-19 supported systemic effect T-cell therapeutic Tocilizumab treat Treatment [DOI] 10.12659/MSM.933973 PMC 바로가기 [Article Type] Editorial
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 EraOncology Published on 2021-07-082022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Administered Affect Anemia approved Blood Cell Chemotherapy clinical development COVID-19 COVID-19 pandemic decrease dose growth factor Health health systems Hospitalization hospitalizations Improving incidence inhibitor Intervention intravenous less lung cancer maintain management myeloprotection myelosuppression neutropenia novel option Patient patients patients receiving placebo patients treated Physicians placebo-controlled clinical study progenitor cell Quality of life receiving recommendation reduced reducing regimen risk of infection Side effect significantly Standard-of-care supportive care thrombocytopenia Treatment [DOI] 10.3389/fonc.2021.697908 PMC 바로가기 [Article Type] Oncology
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques2개의 강력한 중화 항체 조합을 통한 조기 치료는 SARS-CoV-2에 감염된 원숭이에서 임상 결과를 개선하고 바이러스 복제 및 폐 염증을 감소시킵니다.Research Article Published on 2021-07-062022-09-10 Journal: PLoS Pathogens [Category] SARS, 변종, 진단, [키워드] 24 hour 24 hours animal animals anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibodies antibody antibody combination clinic clinical development Clinical outcome Clinical signs Clinical studies clinical testing Combination combinations controls COVID-19 COVID-19 disease develop dose early infection effective extension group half-lives High dose high risk histology Human IMPROVE infected individual Infection inoculated interstitial pneumonia intra-tracheally intranasally intravenously investigated less Lower respiratory tract lung Lung inflammation macaque maintain monoclonal antibodies monoclonal antibody mutations neutralize neutralizing antibody neutralizing monoclonal antibodies Placebo progression promise Prophylactic provide reduce reduced respiratory respiratory tract rhesus rhesus macaque SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease shown significantly Support tested therapeutic efficacy therapeutic intervention Therapeutic strategies three groups treated Treatment upper and lower respiratory tract variant Viral Viral variants virus replication [DOI] 10.1371/journal.ppat.1009688 PMC 바로가기 [Article Type] Research Article
Lipopeptides for Vaccine DevelopmentReview Published on 2021-07-062022-10-04 Journal: Bioconjugate chemistry [Category] 비임상, [키워드] adjuvants Antigen antigens Cancer clinical development COVID-19 CSK derivative described development example Hepatitis highlight immunogenic Immunological response immunotherapies Immunotherapy include Infectious disease Influenza linear lipopeptide malaria peptides Research sequence shown Structure Toll-like receptor agonist treat Vaccine Vaccine development [DOI] 10.1021/acs.bioconjchem.1c00258 PMC 바로가기 [Article Type] Review
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models동물 모델에서 SARS-CoV-2에 대한 DNA 백신 후보 ZyCoV-D의 면역원성 가능성Article Published on 2021-07-052022-09-12 Journal: Vaccine [Category] MERS, SARS, 진단, [키워드] ACE-2 animal model Antibody Response binding candidate vaccine China clinical development conducted coronavirus 2 COVID-19 vaccine deaths DNA DNA plasmid DNA vaccine dose E. coli cell effort elevated elicited enzyme evaluated evidenced gene encoding globe IFN-γ include induce Infection mice MNT neutralizing antibody PCT Plasmid RBD receptor Receptor binding domain respiratory responsible S protein SARS-CoV-2 spike Spread the SARS-CoV-2 virus the spike protein trials virus ZyCoV-D. [DOI] 10.1016/j.vaccine.2021.05.098 PMC 바로가기 [Article Type] Article